Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;37(10):982-991.
doi: 10.1177/02698811231205688. Epub 2023 Oct 16.

Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)

Matthew Kt McAdam  1 , Ross J Baldessarini  2   3 , Andrea L Murphy  1   4 , David M Gardner  1   4
Affiliations

Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)

Matthew Kt McAdam et al. J Psychopharmacol. 2023 Oct.

Abstract

Background: Expert consensus-based clinically equivalent dose estimates and dosing recommendations can provide valuable support for the use of drugs for psychosis in clinical practice and research.

Aims: This second International Consensus Study of Antipsychotic Dosing provides dosing equivalencies and recommendations for newer drugs for psychosis and previously reported drugs with low consensus.

Methods: We used a two-step Delphi survey process to establish and update consensus with a broad, international sample of clinical and research experts regarding 26 drug formulations to obtain dosing recommendations (start, target range, and maximum) and estimates of clinically equivalent doses for the treatment of schizophrenia. Reference agents for equivalent dose estimates were oral olanzapine 20 mg/day for 15 oral and 7 long-acting injectable (LAI) agents and intramuscular haloperidol 5 mg for 4 short-acting injectable (SAI) agents. We also provide a contemporary list of equivalency estimates and dosing recommendations for a total of 44 oral, 16 LAI, and 14 SAI drugs for psychosis.

Results: Survey participants (N = 72) from 24 countries provided equivalency estimates and dosing recommendations for oral, LAI, and SAI formulations. Consensus improved from survey stages I to II. The final consensus was highest for LAI formulations, intermediate for oral agents, and lowest for SAI formulations of drugs for psychosis.

Conclusions: As randomized, controlled, fixed, multiple-dose trials to optimize the dosing of drugs for psychosis remain rare, expert consensus remains a useful alternative for estimating clinical dosing equivalents. The present findings can support clinical practice, guideline development, and research design and interpretation involving drugs for psychosis.

Keywords: Antipsychotics; Delphi survey; consensus; dosing schedule; schizophrenia; therapeutic equivalency.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

See all similar articles

Cited by

References

    1. Acadia Pharmaceuticals Inc, USA (2020) Nuplazid (pimavanserin, FDA). Product Label, November.
    1. Aichhorn W, Whitworth AB, Weiss EM, et al. (2007) Differences between men and women in side effects of second-generation antipsychotics. Der Nervenarzt 78: 45–52. DOI: 10.1007/s00115-006-2112-0. - DOI - PubMed
    1. Alkermes Inc, USA (2021) Aristada (aripiprazole lauroxil, FDA). Product Label, March.
    1. Allergan, USA Inc (2017) Saphris (asenapine, FDA). Product Label, February.
    1. Allergan, USA Inc (2022) Vraylar (cariprazine, FDA). Product Label, 16 December.

Publication types

MeSH terms